LALF$_{32-51}$-E7, a HPV-16 therapeutic vaccine candidate, forms protein body-like structures when expressed in *Nicotiana benthamiana* leaves

Romana J. R. Yanez$^1$, Renate Lamprecht$^1$, Milaid Granadillo$^2$, Isis Torrens$^2$, Elsa Arcalís$^3$, Eva Stöger$^3$, Edward P. Rybicki$^{1,4}$ and Inga I. Hitzeroth$^1$*

$^1$Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa  
$^2$Center for Genetic Engineering and Biotechnology, Havana, Cuba  
$^3$Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria  
$^4$Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

**Summary**  
High-risk human papillomaviruses (HPVs) cause cervical cancer, and while there are good prophylactic vaccines on the market, these are ineffective against established infections, creating a clear need for therapeutic vaccines. The HPV E7 protein is one of the essential oncoproteins for the onset and maintenance of malignancy and is therefore an ideal therapeutic vaccine target. We fused the HPV-16 E7 protein to the *Limulus polyphemus* antilipopolysaccharide factor (LALF$_{32-51}$), a small hydrophobic peptide that can penetrate cell membranes and that has immunomodulatory properties. LALF$_{32-51}$-E7 was transiently expressed in *Nicotiana benthamiana*, and we previously determined that it accumulated better when targeted to chloroplasts compared to being localized in the cytoplasm. Subsequently, we aimed to prove whether LALF$_{32-51}$-E7 was indeed associated with the chloroplasts by determining its subcellular localization. The LALF$_{32-51}$-E7 gene was fused to one encoding enhanced GFP to generate a LG fusion protein, and localization was determined by confocal laser scanning microscopy and transmission electron microscopy (TEM). The fluorescence observed from chloroplast-targeted LG was distinctively different from that of the cytoplasmic LG. Small spherical structures resembling protein bodies (PBs) were seen that clearly localized with the chloroplasts. Larger but less abundant PB-like structures were also seen for the cytoplasmic LG. PB-like structure formation was confirmed for both LG and LALF$_{32-51}$-E7 by TEM. LALF$_{32-51}$-E7 was indeed targeted to the chloroplasts by the chloroplast transit peptide used in this study, and it formed aggregated PB-like structures. This study could open a new avenue for the use of LALF$_{32-51}$ as a PB-inducing peptide.

**Introduction**  
Recombinant proteins have a wide range of applications in the industrial, biomedical and biological research fields. There is a high demand for recombinant proteins, which in turn requires efficient and scalable production systems. Current methods of production of these proteins are mostly based on the use of mammalian, insect or microbial cell cultures, which necessarily rely on bioreactors and on expensive growth media. Plants provide an alternative platform for the expression of recombinant proteins that is potentially more cost-effective than conventional methods and that is also highly scalable (Fischer, 2013; Pogue and Holzberg, 2012; Rybicki, 2009; Sainsbury et al., 2007; Yusibov et al., 2006).

One of the factors that can significantly increase yields in plant expression systems is the specific subcellular localization of the recombinant protein. Different compartments can be used, such as chloroplasts, the endoplasmic reticulum (ER), storage vacuoles, the apoplast and peroxisomes, depending on the requirements of the target protein (Benchabane et al., 2008; Fischer et al., 2004; Karg and Kallio, 2009; Maclean et al., 2007; Meyers et al., 2008; Straitfield et al., 2003). Of these, chloroplast localization is one of the most used and most successful options for increasing the accumulation of specific proteins (Daniell et al., 2009; Hofbauer et al., 2014; Lakshmi et al., 2013; Zahn et al., 2016).

For subcellular localization after nuclear transcription, whether this is in stable nuclear transformants or transiently transformed plant cells, transit peptides are genetically fused to the protein of interest. The proteins are translated in the cytoplasm of the plant cells and subsequently transported to the target organelle. The generally higher yields obtained by transient expression, combined with a further increase in protein accumulation and protein stability away from the cytoplasm, make this an attractive prospect for molecular farming (Fischer et al., 2004; Rybicki, 2010). In particular, our group has found the use of the rbcS1 gene-derived chloroplast transit peptide (CTP) from the RuBisCO small subunit of...
Solanum tuberosum to be highly effective for improving the accumulation of a number of recombinant proteins (Maclean et al., 2007; Meyers et al., 2008).

High-risk human papillomaviruses (HPVs) cause 99.7% of cervical cancer cases (Parkin and Bray, 2006; de Villiers, 2013; Zur Hausen, 2002). There are approximately 530,000 new cases of cervical cancer and 270,000 deaths per year (World Health Organization 2016). HPV-16 and -18 are the most prevalent types worldwide, causing more than 70% of cervical cancer cases. Besides cervical cancer, high-risk HPVs also cause vaginal, vulvar, penile, anal and oropharyngeal cancers (Parkin and Bray, 2006; Zur Hausen, 2002, 2009).

Currently, there are three commercially available prophylactic vaccines for HPVs, all of which consist of the HPV major coat protein L1 assembled into virus-like particles specific for target HPV types. The vaccines are the bivalent (HPV-16 + 18) Cervarix® (GlaxoSmithKline Inc., Brentford, London, UK), the quadrivalent (HPVs 6, 11, 16 and 18) Gardasil® (Merck & Co., Kenilworth, New Jersey, US) and the new nonavalent Gardasil® 9 (Merck 2014). However, these vaccines are not effective in eliminating pre-existing infections (Hildesheim et al., 2007, 2016; Hung et al., 2008). Therefore, the large number of individuals already infected with HPVs, and those who have developed malignancies, do not benefit from the current vaccines. In addition, these vaccines are expensive and unless sponsored by the state or other organizations, they are not accessible to low-income populations. New types of vaccines are therefore needed that can eliminate established infections, and that are also more accessible to poorer communities (Giorgi et al., 2010; Hildesheim et al., 2007).

The HPV E7 protein is one of the two viral oncoproteins that are essential for the onset and maintenance of malignancy, and is therefore an ideal therapeutic vaccine target. Granadillo et al. (2011) developed a HPV-16 therapeutic vaccine candidate consisting of the HPV-16 E7 oncoprotein fused to a peptide derived from the Limulus polyphemus anti-lipopolysaccharide factor (LALF32-51). This is a small and hydrophobic peptide that can penetrate cell membranes and that has immunomodulatory properties (Granadillo et al., 2011, 2015). The fusion to HPV-16 E7 improved both the immunogenicity and antigen presentation of E7 in animal experiments, and LALF32-51-E7 showed promising results for the treatment of already established HPV-16 infections and tumours (Granadillo et al., 2011, 2015).

Accordingly, we investigated the expression of LALF32-51-E7 in Nicotiana benthamiana leaves as an alternative to bacterial expression systems, for providing a more accessible HPV therapeutic vaccine candidate. We targeted it to the chloroplasts to determine whether that would enhance accumulation, as we previously detected only very low expression levels when the protein was targeted to the cytoplasm. Indeed, LALF32-51-E7 accumulated to higher levels when targeted to the chloroplasts of N. benthamiana leaves (up to 0.56% of total soluble proteins, TSP) than when not targeted to any cell compartment (up to 0.017% TSP) (Yanez et al., 2017). In order to prove that this protein was indeed being targeted to the plant chloroplasts, it was fused to EGFP and its subcellular localization was determined by fluorescence confocal laser scanning microscopy (CLSM). As LALF32-51 is a cell membrane-penetrating peptide (Granadillo et al., 2011), it was also desirable to determine whether LALF32-51-E7 interacted with the plant cell interior membranes.

## Results

### Optimization of LG expression in N. benthamiana leaves

The LALF32-51-E7 gene was genetically fused to one encoding the enhanced green fluorescent protein (EGFP), creating the LG gene construct. This was cloned into the replicative vectors pRIC3.0 and pRIC3.0-cTP, creating the constructs LG and cTP-LG, respectively (Figure 1). Final constructs were then electroporated into competent Agrobacterium cells.

To determine the best conditions for the expression of LG in N. benthamiana leaves, Agrobacterium suspensions of different optical densities (OD600) were used to syringe-infiltrate leaves, and LG expression was monitored for 5 days postinfiltration (dpi) by UV-light visualization. Leaves infiltrated with the positive control pRIC3.0-EGFP fluoresced green throughout the experiment, as expected (Figure 2). Uninfiltarted leaves and leaves infiltrated with an empty version of the pRIC3.0 vector fluoresced red, except in areas of leaf damage such as at the points of infiltration where a white-blue fluorescence was seen 5 dpi. Leaves infiltrated with LG and cTP-LG fluoresced green on 3 and 5 dpi regardless of the OD600 used. However, higher OD600 and longer incubation periods were associated with more damage symptoms and lower green fluorescence.

For fluorescence confocal laser scanning microscopy (CLSM), healthy undamaged leaf tissue was desirable. Therefore, OD600 of 0.25–0.5, and 3 dpi were considered optimal conditions for LG expression from both vectors.

### Confirmation of LG expression by immunoblotting

The expression of LG was confirmed by anti-GFP immunoblots of LG and cTP-LG crude extracts. The LG- and cTP-LG-containing extracts showed the same banding patterns, with both displaying high molecular weight aggregates that were not disrupted by boiling with sodium dodecyl sulphate (SDS) and beta-mercaptoethanol and that were larger than 190 kDa. Furthermore, the most distinct band for both samples appeared at the same molecular weight, of approximately 50 kDa (Figure 3).

### Subcellular localization of LG by fluorescence confocal laser scanning microscopy

Once the optimal conditions were determined for the expression of LG, leaves were vacuum-infiltrated with Agrobacterium tumefaciens grown to the optimal OD600 and were analysed by confocal laser scanning microscopy at 3 dpi. Young plants were used as their leaves are thinner than those of older plants: this allowed for appropriate leaf sectioning and better visualization.

In cells expressing the positive control, green fluorescence could be seen evenly distributed in the cytoplasm. No green fluorescence was seen inside the chloroplasts as these appeared as black or empty spheres in the green channel, and no yellow colour was detected when the green and red channels were merged. This was typical of a cytoplasm-localized protein (Figure 4a). No green fluorescence was observed in samples of the negative controls, pRIC3.0 empty vector (Figure 4b) and uninfiltarted leaves (not shown), as expected, and only chloroplasts were seen by red autofluorescence.

The fluorescence pattern in the cytoplasmic LG samples resembled that of the positive control, however, it was less intense (Figure 4c), as previously observed in the optimization experiments. Besides the evenly spread green fluorescence within the plant cells, large bright globular structures could also be seen.
that resembled protein bodies (PBs; Figure 4d, yellow arrows). These globular structures were not as common as the ones seen for the cTP-LG, but they were observed in two rounds of independent experiments.

Interestingly, cells expressing the cTP-LG presented a very different fluorescence pattern. The cTP-LG was seen as numerous bright dots also resembling PBs, but which were smaller and more abundant than those seen in some cytoplasmic LG samples (Figure 4e–f). The distribution of these PB-like structures followed the distribution of the chloroplasts, and they appeared yellow when seen at a lower magnification (Figure 4f, white arrows). When inspected at a higher magnification, the cTP-LG PB-like structures appeared to be mostly at the periphery of the chloroplasts (Figure 4e, blue arrow). However, no cTP-LG was seen separated from chloroplasts, even though chloroplasts that did not have cTP-LG PB-like structures associated with them could be seen.

Colocalization profiles of LG and cTP-LG with chloroplasts

Fluorescence microscopy images were analysed using the colocalization settings on the Zeiss microscope Zen software (Figure 5). In the positive control, overlapping of the red and green fluorescence curves was not common, as expected, indicating that the EGFP was not localized inside the chloroplast (Figure 5a). The negative control gave only a red fluorescence curve (Figure 5b). The curve pattern for the cytoplasmic LG was similar to that of the positive control, except that the green fluorescence intensity was lower (Figure 5c). The green and red fluorescence curves for the cTP-LG, however, followed the same pattern—as one increased, so did the other. This indicated that the cTP-LG was associated with the chloroplasts (Figure 5d). Here, the green fluorescence curve was at times very high, suggesting that the PB-like structures seen for the cTP-LG contained very concentrated LG.

Confirmation of protein body-like structure formation by transmission electron microscopy

To confirm whether LALF32-51-E7 and LG formed PB-like structures, agro-infiltrated leaves were fixed and positively stained for visualization by transmission electron microscopy (TEM). Large protein aggregates were observed for the cytoplasmic LALF32-51-E7 and cTP-LALF32-51-E7. These were electron-dense, irregular or spherical in shape and larger than 1 μm (Figure 6a–b, white arrows). Similar structures were observed for LG and cTP-LG: these were larger than 1 μm for the cytoplasmic LG and smaller for the cTP-LG (Figure 6c–d). These structures were electron-dense and contained electron-lucent patches. These results confirmed that LALF32-51-E7 forms PB-like structures. It could be seen that the cTP-LALF32-51-E7 and cTP-LG aggregates were located between the thylakoid stacks within the chloroplasts; however, it was not possible to determine whether the structures observed were membrane-bound.

Spherical structures that were highly electron-dense and smaller than the LALF32-51-E7 PB-like structures were observed in all samples (Figure 6, black arrows). These were identified as oil droplets and were also present in negative control samples (not shown).
Predicted targeting peptides encoded within the LALF\textsubscript{32-51}-E7 and LG amino acid sequences

To confirm whether the observations described above were not a result of cryptic targeting peptides present within the LALF\textsubscript{32-51}-E7 and LG amino acid sequences, these were analysed using the TargetP and ChloroP prediction programmes (http://www.cbs.dtu.dk/services/TargetP/; http://www.cbs.dtu.dk/services/ChloroP/). No targeting sequences were identified when the LALF\textsubscript{32-51}-E7 and LG amino acid sequences were submitted. However, when the cTP-LALF\textsubscript{32-51}-E7 and cTP-LG amino acid sequences were submitted, the presence of a cTP was indicated and a chloroplast localization was predicted with RC-values of 1 and 2, respectively. This indicated that the prediction was carried out with a high degree of confidence.

Figure 2 Optimization of LG expression in syringe-infiltrated N. benthamiana leaves. Plants infiltrated with pRIC3.0-EGFP and pRIC3.0 empty vector were used as positive (+) and negative (−) controls, respectively. Experimental plants were infiltrated with LG and cTP-LG at different OD\textsubscript{600}. Shown here is a representative picture of each vector/OD\textsubscript{600} combination under UV-light (top) and white light (bottom).
Discussion

The production of accessible HPV vaccines is of particular relevance for the developing world, where HPV infections and related malignancies are most prevalent (Giorgi et al., 2010; Stanley, 2006). For this reason, we expressed LALF32-51-E7, a HPV-16 therapeutic vaccine candidate, using plants as an alternative expression platform.

We found that the accumulation levels of LALF32,51-E7 in N. benthamiana leaves were enhanced by 27-fold when targeted to the chloroplasts, compared to protein not targeted to a cell compartment. In order to prove that LALF32,51-E7 was in fact being targeted to the chloroplasts, we fused it to EGFP. As LALF32,51 is a cell membrane-penetrating peptide, it could be possible that it would be associated with the plants’ cell membranes or that it could in fact exit the plant cells. Therefore, determining its subcellular localization seemed to be imperative.

From the images taken during fluorescence CLSM, it could be seen that LG expressed from pRIC3.0 behaved similarly to the positive control, by localizing like a typical cytoplasmic protein. It could also be seen that it formed large PB-like aggregates; however, these were less common and more heterogeneous than those seen in the cTP-LG samples. It has been shown that LALF32,51-E7 forms inclusion bodies in Escherichia coli cells and that it forms large molecular weight aggregates of varying sizes, even after its purification (Granadillo et al., 2013), so this phenomenon was not surprising. This sample also showed a less intense fluorescence than the cTP-LG, agreeing with previous accumulation levels obtained for the untagged cytoplasmic LALF32,51-E7.

The fluorescence pattern seen for the cTP-LG was distinctively different from that of the cytoplasmic LG. The small spherical structures seen for the cTP-LG clearly colocalized with chlorophyll, confirming the association with the chloroplasts. These spherical structures were also comparable in shape and size to the PBs formed by the cTP-γ-Zein-DsRed fusion protein seen by Hofbauer et al. (2014), which were induced by adding the N-terminal portion of mature 27 kDa γ-zein to a reporter protein. These authors reported ectopic PBs found in the stroma and in the intermembrane space of chloroplasts, demonstrating that PB formation and budding do not require ER-specific factors and can happen in different subcellular localizations. The present study suggests that LALF32,51 can also induce PB formation. Although LALF32,51 is much shorter than the N-terminal portion of mature 27 kDa γ-zein, both sequences share an amphipathic character and contain cysteine residues, possibly initiating aggregates by hydrophobic interactions.

Bross et al. (2017) observed similar globular structures when they investigated localization of arogenate dehydratases (ADT) fused to cyan fluorescent protein in N. benthamiana. They postulate that the ADTs were targeted to stromules, which are stroma-filled protrusions of the outer and inner membrane from chloroplasts (Bross et al., 2017). The similarity of these globular structures to the ones observed in our study suggests that the cTP-LG might be targeted to stromules.

Scatter plots of the colocalization of EGFP or LG and chloroplasts were generated. These showed colocalization for all samples except for the negative control, which was not surprising as the EGFP and LG were within the cells’ cytoplasm, surrounding the chloroplasts and other organelles. Fluorescence profiles proved to be more useful: these further illustrated that the cTP-LG was associated with chloroplasts, while no association was seen for the cytoplasmic LG.

Taken together, the fluorescence microscopy results showed that the cTP signal indeed targeted LALF32,51-E7 to the chloroplasts. Furthermore, immunoblots of LALF32,51-E7 and cTP-LALF32,51-E7 (not shown) as well as LG and cTP-LG show these proteins at the same molecular weights of approximately 22 and 50 kDa, respectively. This further confirms that the cTP-LALF32,51-E7 and cTP-LG entered the chloroplasts, as this is an indication that the cTP signal was cleaved during the membrane translocation into the chloroplast stroma (Li and Chiu, 2010).

Chlorophyll pigments are located within the thylakoid membranes in the stromal compartment of chloroplasts. At the resolution at which the fluorescent CLSM images were taken here, it was not possible to differentiate between the chloroplast internal compartments. However, our TEM observations suggest that the cTP-LG and cTP-LALF32,51-E7 PB-like structures are located in the stromal compartment, mostly at a peripheral position within the plastid.

These findings suggest that the LALF32,51 peptide is a potential PB-inducer. If this is the case, LALF32,51 could have significant promise as a fusion partner which enhances the accumulation of other recombinant proteins in plant expression systems, similar to the Zera® peptide, elastin-like polypeptides (ELP) and hydrophobin (Conley et al., 2011; Saberianfar et al., 2016). Its small size is also an advantage. Furthermore, LALF32,51-fusion proteins could also be targeted to the ER in order to possibly generate larger and more numerous PBs. This would in turn further enhance the accumulation levels and stability of recombinant proteins as well as simplifying their purification processes (Conley et al., 2011; Hofbauer et al., 2014; Torrent et al., 2009; Whitehead et al., 2014).

In summary, we have shown how LALF32,51-E7 and LALF-E7-EGFP polypeptides form PB-like structures when targeted to chloroplasts, which are more concentrated and abundant than for the cytoplasmic versions. These results could explain why LALF32,51-E7 accumulated to much higher levels when targeted.
Subcellular localization of LALF32-51-E7
to the chloroplasts than when localized in the cytoplasm in our vaccine production feasibility study (Yanez et al., 2017).

This study was a proof of concept that confirms the importance of subcellular localization, and which further highlights that chloroplasts are a useful compartment to which to target recombinant proteins. This study also opened new avenues for the use of the LALF32-51 peptide as a potential PB-inducer.

Experimental procedures

Bacterial strains and growth conditions

*Escherichia coli*

All constructs were maintained in DH5α chemically competent *E. coli* cells (*E. cloni*, Lucigen). Cells were grown in Luria-Bertani (LB) medium [1.0% tryptone, 0.5% yeast extract, 1.0% NaCl, pH 7.0]. Antibiotic selection was made using 100 μg/mL ampicillin.

*Agrobacterium tumefaciens*

The strain GV3101 containing the helper plasmid pMP90RK was used. Cells were grown in LBB-enriched medium [0.25% tryptone, 1.25% yeast extract, 0.50% NaCl, 10 mM 2-(N-Morpholino) ethanesulphonic acid (MES), pH 5.6], with agitation at 120 r.p.m., at 27 °C for 2–3 days. Antibiotic selection was made using 50 μg/mL carbenicillin, 50 μg/mL rifampicin and 30 μg/mL kanamycin.

Construct generation

The sequence encoding LALF32-51*E7* was kindly made available by the Center for Genetic Engineering and Biotechnology, Havana. The *E7* coding sequence was previously modified to contain a base substitution (T/G) in the codon encoding for the first cysteine to abolish the carcinogenic effect of the protein (Granadillo et al., 2011). The LALF32-51 sequence encodes a small linear peptide containing residues 32–51 from the original LALF.
To fuse LALF32-51-E7 to EGFP, the DNA sequence encoding LALF32-51-E7 was modified to remove the hexa-histidine tag and the stop codon, to add appropriate restriction enzyme (RE) sites and to insert a linker between the two peptides, as shown in Figure 1. The modified LALF32-51-E7 was plant codon-optimized and synthesized by GenScript (Nanjing, China). LALF32-51-E7 was genetically fused to EGFP, and the resulting LG fragment was subcloned into the expression vectors pRIC3.0 and pRIC3.0-cTP using the NcoI/AflIII and the MluI/XhoI restriction sites, respectively.

Electro-competent A. tumefaciens cultures were prepared as described by Wen-jun and Forde (1989) and electroporated as described by Maclean et al. (2007).

Agroinfiltration of N. benthamiana leaves

Recombinant A. tumefaciens cultures were prepared for small-scale agroinfiltration as described by Maclean et al. (2007). For small-scale expression studies, A. tumefaciens cultures were diluted in infiltration medium to final OD600 of 0.25, 0.50 and 1.00 to determine the optimal OD600 for the expression of LG. Two plants were used per construct/OD600 combination. A time trial was carried out to determine the expression profile of pR-LG and pT-LG, as well as to monitor leaf symptoms. This was done by visualizing infiltrated leaves under white light and ultraviolet light (Spectrolite Long Life™ Filter, set at 365 nm) on 3 and 5 dpi, and harvesting plant tissue on the same time points. The construct pRIC3.0-EGFP was used as a positive control at an OD600 of 0.25 as determined by Regnard et al. (2010). As negative control, the pRIC3.0 empty vector was used at an OD600 of 0.5. One plant was used per control. For the constructs, pRIC3.0-LALF32-51-E7 and pRIC-cTP-LALF32-51-E7, A. tumefaciens suspensions at OD600 of 1.0 were used and leaves were harvested on 3 dpi.

Detection of LG by immunoblotting

Protein extraction was carried out by homogenizing leaf material in 2 v/v extraction buffer [8 M urea in 1 M carbonate-bicarbonate buffer, pH 10.6]. For immunoblotting, the primary and secondary antibodies used were mouse monoclonal anti-GFP (Sigma-Aldrich, St Louis, MO, US) and goat anti-Mouse IgG whole molecules conjugated to alkaline phosphatase (AP; Sigma-Aldrich), respectively, at a dilution of 1 : 5000.

Fluorescence confocal laser scanning microscopy (CLSM)

Vacuum-infiltrated leaves were manually sectioned with a razor blade into very fine strips and mounted in distilled water on a glass slide. A cover slip was placed on top of the sections for visualization. Thin leaf sections were imaged using a Zeiss LSM 510 Meta NLO multiphoton confocal microscope and the ZEN 2009 software (Zeiss). The lenses used included a 20× air lens and a 40× water immersion lens (numerical aperture of 1.1). The EGFP was excited by an argon laser at 488 nm, and the emission was detected at 500–550 nm. The chloroplasts were indirectly detected by exciting the chlorophyll by a DPLs laser at 561 nm, and the emission was detected at 650–710 nm. Imaging parameters were fixed for all data acquisition for both rounds of microscopy done.
For colocalization studies, images obtained during sample visualization were analysed using the colocalization set-up on the ZEN software. To accurately set the cross-hairs, single label control samples must be prepared. For the red label sample (chloroplasts), the negative control was used. Due to the nature of the samples, we did not have a green single label. Therefore, the positive control was used. These controls were imaged with the same microscope settings as the experimental sample. All imaging settings, including the crosshair positions, were kept fixed throughout the colocalization analysis.

Transmission electron microscopy

Agro-infiltrated leaf tissue was cut into 1 mm by 3-mm sections and fixed with a 2.5% glutaraldehyde solution overnight (ON) at 4 °C. Leaf sections were washed in 0.1 M phosphate buffer pH 7.2. Leaf sections were further fixed by a 1% osmium tetroxide in phosphate buffer, for 1 h at room temperature (RT), followed by dehydration by sequential immersion in ethanol–acetone solutions of higher content. Finally, the samples were included in Spurr’s resin by sequential immersion in resin dehydration by sequential immersion in ethanol–acetone mixtures of increasing percentages of resin. Ultra-thin sections were positively stained with uranyl acetate and lead citrate and viewed using a JEOL 200CX transmission electron microscope.

Prediction of targeting peptides encoded within LALF_{22-51}E7 and LG

The TargetP and ChloroP server software from the Technical University of Denmark (http://www.cbs.dtu.dk/services/TargetP/; http://www.cbs.dtu.dk/services/ChloroP/) were used to analyse the amino acid sequences of LALF_{22-51}E7 and LG, with and without the CTP amino acid sequence.

Acknowledgements

We thank Dirk Lang and Susan Cooper for the guidance and assistance with the fluorescence CLSM, Keren Cooper and Mohamed Jaffer for helping with TEM sample preparation, sectioning and visualisation and the Poinomiyelitis Research Foundation and the National Research Foundation of South Africa for research funding.

Conflict of interest

The authors declare no conflict of interest.

References

Benchabane, M., Goulet, C., Rivard, D., Faye, L., Gomard, V. and Michaud, D. (2008) Preventing unintended protelysis in plant protein biofactories. Plant Biotechnol. J. 6, 633–648.

Bross, C.D., Howes, T.R., Abolhassani Rad, S., Kjävik, O. and Kohalni, S.E. (2017) Subcellular localization of Arabidopsis aroagene dehydratases suggests novel and non-enzymatic roles. J. Exp. Bot. 68, 1425–1440.

Conley, A.J., Joensuu, J.J., Richman, A. and Menassa, R. (2011) Protein body-inducing fusions for high-level production and purification of recombinant proteins in plants. Plant Biotechnol. J. 9, 419–433.

Daniell, H., Singh, N.D., Mason, H. and Streetfield, S.J. (2009) Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci. 14, 669–679.

Fischer, R. (2013) Plant-derived biopharmaceuticals: moving plant-derived antibodies and vaccines towards clinical trials.

Fischer, R., Stoger, E., Schillberg, S., Christou, P. and Twyman, R.M. (2004) Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol. 7, 152–158.

Giorgi, C., Francioni, R. and Rybicki, E.P. (2010) Human papillomavirus vaccines in plants. Expert Rev. Vaccines. 9, 913–924.

Granadillo, M., Vallespi, M.G., Batte, A., Mendoza, O., Soria, Y., Lugo, V.M. and Torrens, I. (2011) A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Vaccine, 29, 920–930.

Granadillo, M., Batte, A., Lugo, V.M., Musacchio, A., Bequet-Romero, M., Betancourt, L., Besada, V., et al. (2013) Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen. Springerplus, 2, 12.

Granadillo, M., Alfonso, A.B., Vallespi, M.G., Batte, A., Soria, Y., Brown, E., Limonta, M., et al. (2015) The LALF_{32-51} peptide as component of HPV therapeutic vaccine circumvents the alu-mediated inhibition of IL-12 and promotes a Th1 response. J. Cell Immunother. 2, 44–51.

Hildesheim, A., Herrero, R., Wahochiler, S., Rodriguez, A.C., Solomon, D., Bratti, M.C., Schiller, J.T., et al. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA, 298, 743–753.

Hildesheim, A., Gonzalez, P., Kremen, A.R., Wahochiler, S., Schussler, J., Rodriguez, A.C., Pomas, C., et al. (2016) Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. J. Exp. Bot. 67, 212.e1–212.e15. https://doi.org/10.1007/s10704-016-0201-1.

Hofbauer, A., Peters, J., Arcalis, E., Rademacher, T., Lampel, J., Eudes, F.F., Vitale, A., et al. (2014) The induction of recombinant protein bodies in different subcellular compartments reveals a cryptic plastid-targeting signal in the 27Da γ-Zein sequence. Front. Bioeng. Biotechnol. 2, 6. https://doi.org/10.3389/fbioe.2014.00067.

Hung, C.F., Ma, B., Monie, A., Tsen, S.W. and Wu, T.C. (2008) Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin. Biol. Ther. 8, 421–439.

Karg, S.R. and Kallio, P.T. (2009) The production of biopharmaceuticals in plant systems. Biotechnol. Adv. 27, 879–894.

Lakshmi, P.S., Verma, D., Yang, X., Lloyd, B. and Daniel, H. (2013) Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bioencapsulation, stability and functional evaluation in vitro. PLoS ONE, 8, e54708. https://doi.org/10.1371/journal.pone.0054708.

Li, H. and Chu, C.-C. (2010) Protein transport into chloroplasts. Annu. Rev. Plant Biol. 61, 157–180.

Maclean, J., Koekemoer, M., Oliver, A.J., Stewart, D., Hitzeroth, I., Rademacher, T., Fischer, R., et al. (2007) Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J. Gen. Virol. 88, 1460–1469.

Merck. (2014) FDA Approves Merck’s HPV Vaccine, GARDASIL® 9, to Prevent Cancers and Other Diseases Caused by Nine HPV types—including Types that Cause About 90% of Cervical Cancer Cases Dateline City: GARDASIL 9 includes the greatest number of HPV types in any vaccine. Available at: http://www.mercknewsroom.com/news-release/precription-medicine-news/fda-approves-mercks-hpv-vaccine-gardasil9-prevent-cancers-an. Accessed 22 Jul 2015.

Meyer, A., Chakayya, E., Shephard, E., Tanzer, F.L., Mackan, J., Lynch, A., Williamson, A.-L., et al. (2008) Expression of HPV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol. 8, 53. https://doi.org/10.1186/1472-6750-8-53.

Parkin, D.M. and Bray, F. (2006) The burden of HPV-related cancers. Vaccine, 24, 5311–5315.

Pogue, G.P. and Holzberg, S. (2012) Transient virus expression systems for recombinant protein expression in dicot- and monocotyledonous plants. In Plant Science (Dhal, N.K. and Sahu, S.C., eds.), pp. 191–216. California: InTech.

Regnard, G.L., Hailey-Stott, R.P., Tanzer, F.L., Hitzeroth, I.J. and Rybicki, E.P. (2010) High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol. J. 8, 38–46.

Rybicki, E.P. (2009) Plant-produced vaccines: promise and reality. Drug Discov. Today, 14, 16–24.

Rybicki, E.P. (2010) Plant-made vaccines for humans and animals. Plant Biotechnol. J. 8, 620–637.

© 2017 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 16, 628–637.
Saberianfar, R., Sattarzadeh, A., Joensuu, J.J., Kohalmi, S.E. and Menassa, R. (2016) Protein bodies in leaves exchange contents through the endoplasmic reticulum. *Front. Plant Sci.* **7**, 693. https://doi.org/10.3389/fpls.2016.00693.

Sainsbury, F., Lavoie, P.-O., D’Aoust, M.-A., Vézina, L.-P. and Lomonossoff, G.P. (2007) Expression of multiple proteins using full-length and deleted versions of cowpea mosaic virus RNA-2. *Plant Biotechnol. J.* **6**, 82–92.

Stanley, M. (2006) HPV vaccines. *Best Pract. Res. Clin. Obstet. Gynaecol.* **20**, 279–293.

Streetfield, S.J., Lane, J.R., Brooks, C.A., Barker, D.K., Poage, M.L., Mayor, J.M. and Lamphear, B.J., (2003) Corn as a production system for human and animal vaccines. *Vaccine* **21**, 812–815.

Torrent, M., Llompart, B., Lasserre-Ramassamy, S., Llop-Tous, I., Bastida, M., Marzabal, P., Westerholm-Parvinen, A., et al. (2009) Eukaryotic protein production in designed storage organelles. *BMC Biol.* **7**, 1–14.

Vallespi, M.G., Colas, M., Garay, H., Reyes, O., Araña, M. and Araña, M.J. (2004) Differential regulation of Th1/Th2 in relevant tissues for sepsis pathogenesis with a Limulus anti-LPS factor-derived peptide increases survival in Gram-positive sepsis. *Int. Immunopharmacol.* **4**, 1343–1351.

de Villiers, E.-M. (2013) Cross-roads in the classification of papillomaviruses. *Virology* **445**, 2–10.

Wen-jun, S. and Forde, B.G. (1989) Efficient transformation of *Agrobacterium* spp. by high voltage electroporation. *Nucleic Acids Res.* **17**, 8385.

Whitehead, M., Ohschläger, P., Almajidi, F.N., Alloza, L., Marzábal, P., Meyers, A.E., Hitzeroth, I.I., et al. (2014) Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice. *BMC Cancer* **14**, 367.

World Health Organization. (2016) WHO | Human papillomavirus (HPV). In: Fact sheet. http://www.who.int/immunization/diseases/hpv/en/. Accessed 18 Aug 2016.

Yanez, R.J.R., Lamprecht, R., Granadillo, M., Weber, B., Torrens, I., Rybicki, E.P. and Hitzeroth, I.I. (2017) Expression optimization of a cell membrane-penetrating Human Papillomavirus type 16 therapeutic vaccine candidate in *Nicotiana benthamiana*. *PLoS ONE* **12**, e0183177. https://doi.org/10.1371/journal.pone.0183177.

Yusibov, V., Rabindran, S., Commandeur, U., Twyman, R.M. and Fischer, R. (2006) The potential of plant virus vectors for vaccine production. *Drugs R D* **7**, 203–217.

Zahin, M., Joh, J., Khanal, S., Husk, A., Mason, H., Warzecha, H., Ghim, S. et al. (2016) Scalable production of HPV16 L1 protein and VLPs from tobacco leaves. *PLoS ONE* **11**, e0160995. https://doi.org/10.1371/journal.pone.0160995.

Zur Hausen, H. (2002) Papillomaviruses and cancer: from basic studies to clinical application. *Nat. Rev. Cancer* **2**, 342–350.

Zur Hausen, H. (2009) Papillomaviruses in the causation of human cancers—a brief historical account. *Virology* **384**, 260–265.